Beyond PD-1/PD-L1: Reprogramming the Gynecologic Tumor Microenvironment by Targeting TIGIT and Myeloid Suppression

Area of Science:

• Oncology
• Immunology
• Gynecologic Oncology

Background:

• Immune checkpoint inhibitors targeting PD-1/PD-L1 have limited efficacy in gynecologic cancers, particularly ovarian carcinoma.
• Therapeutic resistance is driven by an immunosuppressive tumor microenvironment (TME) involving regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and inhibitory cytokines.
• TIGIT acts as a key checkpoint regulator, influencing T-cell exhaustion and NK-cell dysfunction.

Purpose of the Study:

• To review the current understanding of the gynecologic TME.
• To delineate the synergistic mechanisms of dual PD-1 and TIGIT blockade.
• To propose a framework for accelerating biomarker-driven therapeutic development.

Main Methods:

• Literature review synthesizing current knowledge on TME and TIGIT/PD-1 synergy.
• Critical evaluation of ongoing clinical trials for dual checkpoint blockade.
• Proposal of an integrative framework using advanced technologies.

Main Results:

• The immunosuppressive TME in gynecologic malignancies is a complex network that limits immunotherapy efficacy.
• Dual blockade of PD-1 and TIGIT is a mechanistically sound strategy to overcome this resistance.
• Synergy between PD-1 and TIGIT blockade addresses multiple immunosuppressive pathways.

Conclusions:

• Overcoming TME-mediated resistance in gynecologic cancers requires targeting multiple checkpoints, including PD-1 and TIGIT.
• Integrated approaches combining spatial transcriptomics and single-cell profiling are crucial for biomarker discovery.
• Accelerating the development of effective immunotherapies for gynecologic malignancies is achievable through rational combination strategies.